Selective JAK Inhibition in RA vs PV - Poll - MDSpire

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

  • By

  • Julia Cipriano

  • February 13, 2026

  • 3 min

Share

Original Source(s)

Selective JAK Inhibition in RA vs PV

  • by Julia Cipriano

  • February 13, 2026

Related Content

Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease–related spondyloarthritis: insights from a cross-sectional study

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.